KLOW (80 mg)

At a Glance

KLOW is an 80 mg lyophilised blend containing GHK-Cu (50 mg) + TB-500 (10 mg) + BPC-157 (10 mg) + KPV (10 mg). It builds on the GLOW formula by adding KPV — a potent anti-inflammatory tripeptide — making it the most comprehensive blend for recovery contexts involving gut or systemic immune involvement alongside tissue injury.[1][2]

• Reconstitute: Add 3.0 mL bacteriostatic water → 26.7 mg/mL concentration.
• Standard dose: 2,670 mcg (10 units / 0.10 mL) once daily subcutaneous.
• Easy measuring: At 26.7 mg/mL on a U-100 syringe, 1 unit = 0.01 mL ≈ 267 mcg total blend.
• Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks. Note: KLOW solution appears blue due to the GHK-Cu copper chelation — this is normal.

Overview

• Composition: GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg (4:1:1:1 ratio) in an 80 mg lyophilised vial.
• Goal: Comprehensive tissue repair with additional gut-lining and systemic anti-inflammatory support via KPV.[1][2]
• Schedule: Once-daily SC injection for a 4-week cycle; 2–4 weeks off.
• Reconstitution: 3.0 mL BAC water per 80 mg vial → 26.7 mg/mL.
• Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

What You’ll Need

Plan based on a 4-week cycle at 2,670 mcg once daily (28 injections).

• KLOW Vials (80 mg each): One 80 mg vial provides a full 30-day supply at 2,670 mcg/day → 1 vial per cycle.
• Insulin Syringes (U-100, 0.3 mL / 30-unit preferred): 28 injections → 28 syringes per 4-week cycle.
• Bacteriostatic Water (10 mL bottles): 3.0 mL per vial → 1 × 10 mL bottle per 3 vials.
• Alcohol Swabs: 2 per injection → 56 swabs per 4-week cycle.

How to Reconstitute

1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
2. Draw 3.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the inner vial wall to minimise foaming; do not inject directly onto the powder cake.
4. Gently swirl or roll until fully dissolved — do not shake. Note: KLOW solution will appear blue due to the copper chelation of GHK-Cu; this is normal and expected.
5. Label with reconstitution date and all four component names; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Dosing Schedule

Frequency: Inject once daily subcutaneously. Begin at the half-dose for the first 1–2 weeks to assess tolerability, then advance to the standard 2,670 mcg dose. At 26.7 mg/mL, the 80 mg vial provides 30 days at the standard dose — a full 4-week cycle.

Cycle structure: 4 weeks on, 2–4 weeks off. The rest period allows assessment of healing progress before deciding on a second cycle.

Protocol Details

• Weeks 1–2 (starting): 1,335 mcg (5 units / 0.05 mL) once daily — half-dose tolerability phase.[2]
• Weeks 3–4 (standard): 2,670 mcg (10 units / 0.10 mL) once daily.
• Each standard injection delivers: ~1,670 mcg GHK-Cu + ~335 mcg TB-500 + ~335 mcg BPC-157 + ~335 mcg KPV.
• Injection site: Abdomen, thigh, or upper arm (rotate daily). For injuries with a strong local component, proximity to injury site enhances BPC-157's local effects.

Storage

• Lyophilised: Store at −20 °C (−4 °F) or below; protect from moisture and light.
• Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
• Blue colour: GHK-Cu copper chelation gives the solution a characteristic blue colour — inspect for clarity but do not expect the colourless appearance of other peptides.

How KLOW Works

KLOW combines four peptides into a single coordinated repair and anti-inflammatory protocol:

• GHK-Cu (50 mg — primary component): Copper tripeptide that modulates 4,000+ repair genes, stimulates collagen synthesis (types I, III, IV), balances MMPs/TIMPs, and delivers bioavailable copper to cuproenzymes (lysyl oxidase, SOD1).[2]
• TB-500 (10 mg): Binds G-actin for systemic cell migration, angiogenesis, anti-inflammatory, and anti-fibrotic signalling body-wide.
• BPC-157 (10 mg): Drives local repair via FAK-paxillin pathway, VEGF upregulation, and NO-pathway normalisation; provides additional gut mucosal protection.[3]
• KPV (10 mg — KLOW's distinguishing component): The C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. Penetrates intestinal epithelial cells, inhibits NF-κB to reduce pro-inflammatory cytokines (IL-6, TNF-α) in gut mucosa, and acts on melanocortin receptors (MC1R, MC3R) for systemic immune modulation.[1]

The 4:1:1:1 ratio prioritises GHK-Cu's broad genomic repair foundation while each supporting peptide contributes a distinct, non-overlapping mechanism.

Good to Know

• KLOW solution is normally blue — this is expected and indicates intact GHK-Cu copper chelation. Do not discard on this basis alone.
• KLOW is particularly suited to recovery contexts involving gut inflammation (NSAID use, IBD flares, stress-related gut dysfunction) where KPV's mucosal protection adds meaningful benefit over the GLOW blend.
• WADA-prohibited — TB-500 and BPC-157 are Category S2 non-approved peptides. Athletes under anti-doping rules must not use KLOW.
• Rotate injection sites daily; document dose, site, and any local reactions.
• Gut and immune support: KPV significantly reduced colonic inflammation in experimental colitis, reducing TNF-α, IL-6, and NF-κB activity in intestinal tissue.[1]
• Genomic repair: GHK-Cu modulates 4,000+ genes; 31/66 chronic disease genes shifted toward healthy phenotypes.[2]
• Musculoskeletal repair: BPC-157 and TB-500 components provide local and systemic tissue repair — same evidence base as the Wolverine Stack.[3]
• Blue solution: GHK-Cu's copper chelation produces a characteristic blue colour — document this in protocol notes to avoid confusion.
• WADA status: TB-500 and BPC-157 components are prohibited; GHK-Cu and KPV have no explicit WADA prohibition as of 2025 but KLOW as a blend is non-approved.
• For background on KLOW Blend's mechanism, evidence, and safety profile, see What Is KLOW Blend?.

Tips for Best Results

• Maintain adequate dietary protein (1.2–1.6 g/kg) and vitamin C (collagen cofactor) for GHK-Cu's collagen synthesis effects.
• For gut inflammation contexts, a low-FODMAP or anti-inflammatory diet supports KPV's mucosal repair effects.
• Protect skin from UV exposure during GHK-Cu cycles — new matrix formation increases photosensitivity.
• Avoid NSAIDs during KLOW cycles — they counteract BPC-157's NO-pathway and VEGF repair signalling.

Injection Tips

• Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
• Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
• Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
• Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
• Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.